Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Price Target at $70.75

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been assigned a consensus rating of “Hold” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $70.75.

PBH has been the subject of several research analyst reports. Canaccord Genuity Group reduced their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Finally, Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th.

Prestige Consumer Healthcare Stock Up 0.9%

Prestige Consumer Healthcare stock opened at $54.92 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 2.25. The company’s 50-day moving average is $48.82 and its 200-day moving average is $56.06. The firm has a market capitalization of $2.60 billion, a PE ratio of 15.38, a P/E/G ratio of 1.69 and a beta of 0.34. Prestige Consumer Healthcare has a fifty-two week low of $42.62 and a fifty-two week high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business had revenue of $265.71 million during the quarter, compared to the consensus estimate of $250.34 million. Prestige Consumer Healthcare’s revenue was up 6.5% on a year-over-year basis. During the same period last year, the business posted $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.6 earnings per share for the current year.

Institutional Trading of Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. Massachusetts Financial Services Co. MA raised its position in shares of Prestige Consumer Healthcare by 10.2% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 650,793 shares of the company’s stock worth $40,147,000 after acquiring an additional 60,496 shares in the last quarter. Leeward Investments LLC MA boosted its position in shares of Prestige Consumer Healthcare by 23.3% during the 4th quarter. Leeward Investments LLC MA now owns 387,321 shares of the company’s stock valued at $23,894,000 after purchasing an additional 73,162 shares in the last quarter. Legato Capital Management LLC boosted its position in shares of Prestige Consumer Healthcare by 532.4% during the 4th quarter. Legato Capital Management LLC now owns 27,774 shares of the company’s stock valued at $1,713,000 after purchasing an additional 23,382 shares in the last quarter. Brandes Investment Partners LP grew its stake in Prestige Consumer Healthcare by 93.2% during the fourth quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock worth $37,430,000 after purchasing an additional 292,744 shares during the period. Finally, Bessemer Group Inc. increased its holdings in Prestige Consumer Healthcare by 20.9% in the first quarter. Bessemer Group Inc. now owns 374,691 shares of the company’s stock worth $22,207,000 after purchasing an additional 64,760 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Key Stories Impacting Prestige Consumer Healthcare

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Adjusted EPS was $0.98, exceeding the $0.89 analyst consensus and rising from $0.95 a year earlier. Revenue increased 6.5% year over year to $265.7 million, above the $250.3 million consensus estimate. Prestige Consumer Healthcare Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Organic sales grew 3.2%, led by the gastrointestinal and dermatological categories, suggesting underlying demand remained resilient despite a challenging consumer environment.
• Positive Sentiment: Prestige raised fiscal 2027 guidance to revenue of $1.290 billion-$1.315 billion, adjusted EPS of $4.55-$4.65, and adjusted free cash flow of at least $270 million. The revenue outlook includes the recently acquired Breathe Right portfolio and LaCorium Health. Prestige Consumer Healthcare Fiscal 2027 First Quarter Results
• Positive Sentiment: Adjusted free cash flow rose to $83.7 million, and management said the cash generation should support deleveraging. The company also extended $400 million of debt maturities to 2034, moving its closest maturity to 2031.
• Neutral Sentiment: An analyst roundup cited a $70.75 price target, indicating potential upside relative to recent trading levels, though price targets reflect individual estimates rather than company guidance. Analysts Set Prestige Consumer Healthcare Price Target
• Negative Sentiment: GAAP diluted EPS fell to $0.61 from $0.95, while net income declined to $29.2 million from $47.5 million. Gross margin also contracted to 51.3% from 56.2%, and acquisition-related expenses and higher interest costs weighed on reported profitability.
• Negative Sentiment: Prestige ended the quarter with approximately $2 billion of net debt, increasing financial leverage and execution risk as it integrates the new acquisitions.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).